67 episodes

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

PeerView Family Medicine & General Practice CME/CNE/CPE Video Podcast PVI, PeerView Institute for Medical Education

    • Science

PeerView is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

    • video
    Edward J. Fox, MD, PhD - Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings From Stockholm?

    Edward J. Fox, MD, PhD - Current Status and Future Directions in the Treatment of Multiple Sclerosis: What Are the Key Learnings From Stockholm?

    Go online to PeerView.com/UYU860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in neurology discusses new and late-breaking data on current and emerging treatments for multiple sclerosis from the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS 2019). Upon completion of this activity, participants should be better able to: Employ recently presented data related to approved disease-modifying therapies when treating patients with multiple sclerosis, Examine new data on the efficacy, safety, and tolerability of emerging disease-modifying therapies for the treatment of multiple sclerosis, Recognize the potential clinical utility of investigational disease-modifying therapies in the future management of multiple sclerosis

    • 11 min
    • video
    Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient

    Reynold A. Panettieri, Jr., MD - Improving Outcomes in Uncontrolled Moderate-to-Severe Asthma: Choosing the Right Treatment for the Right Patient

    Go online to PeerView.com/EPJ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an asthma expert discusses advances in the understanding of the pathogenesis of asthma and novel targeted treatments that have been developed as a result. Strategies for identifying uncontrolled moderate-to-severe asthma patients who would benefit from these agents and clinical data for the currently available and emerging biologic therapies for asthma treatment are also discussed. Upon completion of this activity, participants should be better able to: Describe the economic impact and quality-of-life burden of moderate-to-severe asthma, Discuss the inflammatory mediators and mechanisms that provide the basis for the phenotypes and endotypes of severe asthma and their relevance to novel biologic therapies, Assess the latest clinical data with regard to efficacy and safety for currently available and emerging biologic therapies for the treatment of severe asthma, Apply treatment for patients with asthma based on symptom severity, disease phenotypes, exacerbation risk, and eligibility for biologic therapies

    • 39 min
    • video
    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Amit Singal, MD, MS - MasterClass & Tumor Board⁠—Joining Forces in Hepatocellular Carcinoma: Enhancing Multidisciplinary Care in an Era of New Therapeutic Solutions

    Go online to PeerView.com/GWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView MasterClass and Tumor Board video activity, based on an educational session from The Liver Meeting® (American Association for the Study of Liver Diseases) in Boston, features a panel of hepatology, oncology, surgery, and interventional radiology experts, who provide their clinical perspectives on cutting-edge science that has validated, newly available systemic treatment options in HCC. Coupled with each MasterClass, the Tumor Board segments feature reflective case-centered discussions on the crucial role that hepatology clinicians serve across the HCC continuum of care. Upon completion of this activity, participants should be better able to: Evaluate the safety and efficacy data of multikinase and checkpoint inhibitors and antiangiogenic therapy indicated for advanced HCC, Summarize emerging clinical evidence on the use of novel systemic options in conjunction with or as an alternative to continued LRT for patients with intermediate HCC, Implement multidisciplinary team-based approaches to develop safe, personalized treatment algorithms that utilize novel components for patients with HCC

    • 1 hr 30 min
    • video
    Robin L. Jones, MD - Putting Tenosynovial Giant Cell Tumor on Notice: Multidisciplinary Treatment and Implications of New Science

    Robin L. Jones, MD - Putting Tenosynovial Giant Cell Tumor on Notice: Multidisciplinary Treatment and Implications of New Science

    Go online to PeerView.com/CSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. PeerView’s latest online activity, based on a live symposium held adjunct to the CTOS 2020 Annual Meeting CTOS in Tokyo, addresses the newest treatment developments for rare and typically benign, tenosynovial giant cell tumor (TGCT), and provides a multidisciplinary look at how novel targeted therapeutics have enhanced the long-standing treatment landscape. This intimate, mentor-based, CME/MOC/CC-certified activity sheds light on a historically difficult-to-treat connective tissue tumor and the science that is providing hope for patients with TGCT. Don’t miss this unique educational opportunity. Upon completion of this activity, participants should be better able to: Discuss the clinical signs and aggressive course of rare connective tissue tumors, including tenosynovial giant cell tumor, Cite the biologic rationale and clinical evidence for the use of targeted options in the management of rare connective tissue tumors, Develop multidisciplinary approaches for the recognition and treatment of connective tissue tumors, including rare nonmalignant disorders

    • 57 min
    • video
    Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

    Mikhail Kosiborod, MD, FACC, FAHA - Reducing Cardiovascular Risks in Patients With Type 2 Diabetes: Identifying Your Role on the Diabetes Management Team

    Go online to PeerView.com/YNQ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView onDemand activity, based on an educational session from the 2019 Scientific Sessions of the American Heart Association in Philadelphia, Pennsylvania, features a panel of cardiology, endocrinology, and primary care experts, who provide their clinical perspectives on assessing patients with type 2 diabetes mellitus (T2DM) who are at high risk for cardiovascular (CV) disease and other risk factors. These experts discuss recent and emerging data for antihyperglycemic agents (ie, GLP-1 receptor agonists and SGLT2 inhibitors) and how to incorporate this practice-changing information into individualized treatment plans for these high-risk patients. Upon completion of this activity, participants should be better able to: Screen patients with or at high risk of CV disease for T2DM, Assess individual patients with T2DM for risk factors that frequently complicate diabetes management (ie, history of atherosclerotic CV disease, heart failure, chronic kidney disease, hypoglycemia, obesity), Design individualized treatment regimens that consider and incorporate recent and emerging data for antihyperglycemic agents that have been shown to reduce CV risk in patients with T2DM, Collaborate with multidisciplinary colleagues to successfully reduce CV risk in individual patients with T2DM

    • 1 hr 18 min
    • video
    Matthew R. Weir, MD - Addressing the Disease Burden Associated With Anemia of Chronic Kidney Disease: Expert Insight on the Clinical Potential of HIF-PH Inhibitors

    Matthew R. Weir, MD - Addressing the Disease Burden Associated With Anemia of Chronic Kidney Disease: Expert Insight on the Clinical Potential of HIF-PH Inhibitors

    Go online to PeerView.com/DUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert discusses the management of anemia in patients with chronic kidney disease (CKD) and closely reviews the clinical potential of hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitors in treating CKD-associated anemia. Upon completion of this activity, participants will be able to: Describe the clinical consequences of anemia in patients with chronic kidney disease (CKD), Recognize the rationale for targeting hypoxia-inducible factor (HIF) stabilization with HIF prolyl-hydroxylase (PH) inhibitors as a treatment strategy for anemia because of CKD, Compare current and emerging treatments for CKD-associated anemia in terms of their mechanisms of action, efficacy, and safety, Identify patients with anemia because of CKD who would likely derive benefit from treatment with a HIF-PH inhibitor

    • 41 min

Top Podcasts In Science

Listeners Also Subscribed To